# Atrasentan (VANRAFIA)

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/atrasentan-vanrafia
Canonical HTML page: https://getbiobrief.com/entity/atrasentan-vanrafia

## Recent coverage (1 stories)

### Alport Syndrome Market to Hit 47% CAGR Through 2036 on Gene Therapy Pipeline
2026-07-27 09:04:39 · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report highlights ELX-02 from Eloxx as a potential first-mover gene therapy with an 8-week dosing interval, while big pharma players like Bayer and Novartis advance competitors.
Full story: https://getbiobrief.com/story/alport-syndrome-market-47-cagr-2036-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.